Hormone Therapy in Women

Introduction to Progesterone Therapy

The American Heart Association notes that progesterone receptors are expressed in the vasculature, but their role in cardiovascular disease development remains poorly defined 1
The US Preventive Services Task Force concluded that the chronic disease prevention benefits of hormone therapy are unlikely to outweigh harms in most postmenopausal women 2

Progesterone regulates oxidative metabolism in brain mitochondria and works synergistically with estrogen to protect neuronal function, according to the British Medical Journal 3
Progesterone may help prevent cognitive decline associated with aging, although more research is needed to confirm this effect 3

The 2023 Hypertension guideline notes that progesterone may promote leptin-mediated endothelial dysfunction in obese premenopausal women through aldosterone and endothelial mineralocorticoid receptors, potentially enhancing sodium sensitivity in these women 4

Micronized bioidentical progesterone has demonstrated efficacy for alleviating PMS-related sleep disturbances through its action on GABA-A receptors in the brain, with the strongest evidence supporting its use for sleep improvement rather than anxiety or mood symptoms, as recommended by the European Society for Human Reproduction and Embryology 5
Micronized progesterone minimizes cardiovascular risks compared to synthetic progestogens, has neutral or beneficial effects on blood pressure, and shows one of the best safety profiles regarding thrombotic risk 5
Micronized progesterone does not negatively impact lipid profiles, unlike medroxyprogesterone acetate, as recommended by the National Comprehensive Cancer Network 6

Micronized bioidentical progesterone is contraindicated in women with a history of hormone-dependent cancers, as stated by the National Comprehensive Cancer Network 6
Micronized bioidentical progesterone is not recommended for women with severe peanut allergies, as many formulations contain peanut oil, according to the American College of Obstetricians and Gynecologists 7
Custom compounded bioidentical hormones are not recommended due to lack of data supporting safety and efficacy claims, as advised by the National Comprehensive Cancer Network 6

Oral micronized progesterone is preferred over vaginal administration for optimal anxiolytic metabolite production, and should be administered during the luteal phase only (typically days 14-28 of cycle), with bedtime administration to maximize sleep benefits and minimize daytime sedation, as recommended by the European Society for Human Reproduction and Embryology 5
Symptom improvement should be evaluated after 2-3 cycles, and if no improvement is seen after 3 cycles, alternative treatments should be considered 5